Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 11/20 | 0.46 |
| ▸ | HTR2A | P28223 | 11/20 | 0.46 |
| ▸ | HTR7 | P34969 | 11/20 | 0.46 |
| ▸ | HTR6 | P50406 | 11/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.45 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.39 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.39 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4953313 | 0.89 | HTR1A (0.49) | HTR1AHTR2AHTR7HTR6OPRM1 | |
| SCHEMBL4954789 | 0.89 | OPRM1 (0.45) | HTR1AHTR2AHTR7HTR6OPRM1 | |
| SCHEMBL4952253 | 0.87 | OPRM1 (0.45) | HTR1AHTR2AHTR7HTR6OPRM1 | |
| SCHEMBL4948705 | 0.87 | OPRM1 (0.45) | HTR1AHTR2AHTR7HTR6OPRM1 | |
| SCHEMBL4951614 | 0.86 | OPRM1 (0.44) | HTR1AHTR2AHTR7HTR6OPRM1 | |
| SCHEMBL4948948 | 0.85 | ALDH1A1 (0.43) | HTR1AHTR2AHTR7HTR6OPRM1 | |
| SCHEMBL4951481 | 0.85 | CYP2D6 (0.45) | HTR1AHTR2AHTR7HTR6OPRM1 | |
| SCHEMBL4953715 | 0.85 | MAPT (0.54) | OPRM1OPRK1OPRL1BACE1MEN1 | |
| SCHEMBL4953282 | 0.85 | HTR1A (0.46) | HTR1AHTR2AHTR7HTR6OPRM1 | |
| SCHEMBL4948679 | 0.84 | MEN1 (0.44) | HTR1AHTR2AHTR7HTR6OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306102-A1 | NOVEL SPIROOXYINDOLE COMPOUNDS AND DRUGS CONTAINING SAME | KOWA CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-20080306102-A1 | NOVEL SPIROOXYINDOLE COMPOUNDS AND DRUGS CONTAINING SAME | KOWA CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-20080306102-A1 | NOVEL SPIROOXYINDOLE COMPOUNDS AND DRUGS CONTAINING SAME | KOWA CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306102-A1 | NOVEL SPIROOXYINDOLE COMPOUNDS AND DRUGS CONTAINING SAME | HSD11B1, HSD11B2, HSD3B1 | HTR1A 815/4885HTR2A 1155/4885HTR7 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.